Peptris Technologies out-licenses AI-discovered drug candidate to Revio Therapeutics EP News Bureau Mar 17, 2025 Under the agreement, Revio Therapeutics will hold commercialisation rights to PEPR124 (RT001) in all markets except in BRICS…
